Understanding GUF1: Potential Drug Target Or Biomarker (G60558)
Understanding GUF1: Potential Drug Target Or Biomarker
GUF1, also known as GUF1 variant 1, is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The GUF1 gene is a member of the G-coupled protein family, which includes proteins involved in various cellular processes, including cell signaling, DNA replication, and inflammation.
GUF1 is a single-spaced gene that encodes a protein with 154 amino acid residues. The protein has a molecular weight of approximately 17 kDa and a calculated pI of 5.5. GUF1 is predominantly expressed in human tissues, including brain, heart, liver, and muscle.
The GUF1 gene has been associated with various diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, GUF1 has been implicated in the development and progression of various types of cancer, including breast, ovarian, and colorectal cancer. The protein has also been shown to be involved in neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.
One of the key challenges in studying GUF1 is its expression and function in different tissues and conditions. While the protein is widely expressed in many tissues, its expression and localization to specific cell types and processes are not well understood. This is particularly challenging in the context of neurodegenerative diseases, where the disease is characterized by the progressive loss of brain cells and the development of neurofibrillary tangles.
In order to better understand the function of GUF1, researchers have used various techniques to study its expression and localization. One approach has been to use RNA sequencing (RNA-seq) to identify the global expression patterns of the gene across different tissues and conditions. This has provided insights into the differential expression of GUF1 in different contexts, including cancer, neurodegenerative diseases, and autoimmune disorders.
Another approach has been to study the localization of GUF1 to specific tissues and cell types. For example, researchers have used immunofluorescence microscopy to visualize the expression of GUF1 in different brain regions and cell types, including neurons and glial cells in the developing brain. These studies have provided valuable information about the spatial distribution of the protein and its localization to specific cell types and tissues.
In addition to its expression and localization, GUF1 has also been studied for its potential as a drug target or biomarker. One approach has been to identify potential binding sites within the protein that may be targeted by small molecules or antibodies. This has led to the development of a number of compounds that have been shown to interact with GUF1 and may be potential drug candidates.
Another approach has been to use these compounds to study the efficacy of these compounds as potential therapeutic agents. For example, researchers have used these compounds to treat various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The results of these studies have provided valuable information about the efficacy and safety of these compounds as potential therapeutic agents.
Overall, the GUF1 gene is a promising target for drug development due to its association with various diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the function of GUF1 and its potential as a drug target or biomarker.
Protein Name: GTP Binding Elongation Factor GUF1
Functions: Promotes mitochondrial protein synthesis. May act as a fidelity factor of the translation reaction, by catalyzing a one-codon backward translocation of tRNAs on improperly translocated ribosomes. Binds to mitochondrial ribosomes in a GTP-dependent manner
The "GUF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GUF1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
GUK1 | GULOP | GULP1 | GUSB | GUSBP1 | GUSBP11 | GUSBP12 | GUSBP14 | GUSBP15 | GUSBP17 | GUSBP2 | GUSBP3 | GUSBP4 | GUSBP5 | GUSBP8 | GVINP1 | GVQW3 | GXYLT1 | GXYLT1P3 | GXYLT1P4 | GXYLT1P6 | GXYLT2 | GYG1 | GYG2 | GYPA | GYPB | GYPC | GYPE | GYS1 | GYS2 | GZF1 | GZMA | GZMB | GZMH | GZMK | GZMM | H1-0 | H1-1 | H1-10 | H1-10-AS1 | H1-2 | H1-3 | H1-4 | H1-5 | H1-6 | H1-7 | H1-8 | H1-9P | H19 | H19-ICR | H2AB1 | H2AB2 | H2AB3 | H2AC1 | H2AC11 | H2AC12 | H2AC13 | H2AC14 | H2AC15 | H2AC16 | H2AC17 | H2AC18 | H2AC20 | H2AC21 | H2AC25 | H2AC3P | H2AC4 | H2AC6 | H2AC7 | H2AJ | H2AP | H2AX | H2AZ1 | H2AZ1-DT | H2AZ2 | H2AZ2-DT | H2AZP2 | H2BC1 | H2BC10 | H2BC11 | H2BC12 | H2BC12L | H2BC13 | H2BC14 | H2BC15 | H2BC17 | H2BC18 | H2BC20P | H2BC21 | H2BC26 | H2BC27P | H2BC3 | H2BC4 | H2BC5 | H2BC6 | H2BC7 | H2BC8 | H2BC9 | H2BP1 | H2BP2
